PanoramicaGraficoNotizieSchermataTrader

Morgan Stanley Call 190 ABBV 20.1.../  DE000ME5D2V5  /

Stuttgart
11/11/2024  11:57:36 Var.-0.29 Denaro14:11:27 Lettera14:11:27 Sottostante Prezzo di esercizio Expiration date Tipo di opzione
6.79EUR -4.10% 6.80
Quantità in denaro: 500		 7.00
Quantità in lettera: 500		 AbbVie Inc 190.00 USD 20/12/2024 Call
GlobeNewswire 29/08 Great Place To Work Announces the 2024 Best Workplaces in Asia Representing 6.9 Million Employee Exp...
GlobeNewswire 28/08 Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference
GlobeNewswire 28/08 Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
GlobeNewswire 23/08 NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Confere...
GlobeNewswire 19/08 TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults wit...
GlobeNewswire 15/08 Soleno Therapeutics Announces Updates to its Board of Directors
GlobeNewswire 09/08 Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2...
GlobeNewswire 08/08 CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 08/08 Aligos Therapeutics Strengthens Board with Two New Independent Directors
GlobeNewswire 08/08 Genmab Announces Financial Results for the First Half of 2024
GlobeNewswire 08/08 Genmab Updates 2024 Financial Guidance
GlobeNewswire 08/08 Royalty Pharma Reports Second Quarter 2024 Results
GlobeNewswire 07/08 Alector Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 01/08 Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies i...
GlobeNewswire 01/08 CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024
GlobeNewswire 01/08 NodThera Announces Appointment of Greg Chow as Chief Financial and Business Officer
GlobeNewswire 01/08 Otsuka Pharmaceutical to Acquire Jnana Therapeutics Inc.
GlobeNewswire 31/07 Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors
GlobeNewswire 31/07 Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV111, a CD19 Directed in situ CAR...
GlobeNewswire 30/07 Montara Therapeutics Closes $8 Million Seed Round Led by SV Health Investors’ Dementia Discovery Fun...
GlobeNewswire 28/07 Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzhei...
GlobeNewswire 25/07 Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Tre...
GlobeNewswire 24/07 Emerging Gene Therapies Signal Transformative Shift in Retinal Disorder Treatment, According to Sphe...
GlobeNewswire 24/07 Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital
GlobeNewswire 24/07 OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial fo...